Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas|
- Overall Survival [ Time Frame: 24 months ] [ Designated as safety issue: No ]Patients will be followed for survival every 12 weeks +/- 1 week.
- Progression-Free Survival [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood, tumor tissue, cerebrospinal fluid.
|Study Start Date:||May 2013|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||May 2015 (Final data collection date for primary outcome measure)|
|United States, New Hampshire|
|Dartmouth-Hitchcock Medical Center||Recruiting|
|Lebanon, New Hampshire, United States, 03756|
|Contact: Cancer Research Nurse 800-639-6918 email@example.com|
|Principal Investigator: Arti B Gaur, PhD|
|Principal Investigator: Camilo E Fadul, MD|
|Principal Investigator:||Arti B Gaur, PhD||Dartmouth-Hitchcock Medical Center|